Investment Firm Doubles Down on Biotech Stock, Adds 386,000 Shares, According to Latest SEC Filing
Boxer Capital Management, LLC reported 386,000 shares Kodiak Science (NASDAQ:KOD) shares in its filing on February 17, 2026, with the SEC, trading at an estimated $7.90 million based on quarterly prices.
In a February 17, 2026, SEC filing, Boxer Capital Management, LLC disclosed the purchase of an additional 386,000 shares of Kodiak Sciences. The estimated transaction value was $7.90 million, based on an unadjusted closing price during the October to December 2025 quarter. The value of Kodiak Sciences’ position increased by $19.49 million from the previous filing, an amount that reflects both the purchase of new shares and the appreciation of the share price.
The purchase brought Kodiak Sciences to 6.95% of Boxer Capital Management, a 13F reporting LLC’s AUM.
The top five options after installation:
-
NASDAQ:TNGX: $96.36 million (21.1% of AUM)
-
NASDAQ:RVMD: $31.86 million (7.0% of AUM)
-
NASDAQ: KOD: $31.76 million (7.0% of AUM)
-
NASDAQ:KYMR: $25.61 million (5.6% of AUM)
-
NASDAQ:CELC: $22.44 million (4.9% of AUM)
As of February 17, 2026, Kodiak Sciences shares are trading at $22.66, up 340.0% over the past year, besting the S&P 500 by 318.88 percent.
|
Metric |
Price |
|---|---|
|
Price (as of market close on February 17, 2026) |
$22.66 |
|
Market capitalization |
$1.20 billion |
|
Total revenue (TTM) |
($217.34 million) |
|
One-year price changes |
340.00% |
-
It develops and advances treatments for retinal diseases, with lead candidate KSI-301 in a Phase IIb/III clinical trial targeting wet age-related macular degeneration and other retinal indications.
-
It operates a clinical-stage biopharmaceutical model, generating revenue primarily through future sales of drug candidates currently in development.
-
It is developing treatments for retinal diseases, including age-related macular degeneration and diabetic macular edema.
Kodiak Sciences is a clinical-stage biotechnology company focused on the research and development of novel treatments for retinal diseases. The company’s strategy is focused on using the antibody biopolymer conjugate platform to address important unmet needs in ophthalmology. With a focused pipeline and a lead candidate in recent trials, Kodiak Sciences aims to establish a competitive edge through innovative science and targeted market positioning.
Boxer Capital, a California-based investment firm, recently disclosed the purchase of Kodiak Sciences stock worth $7.9 million. Here are some key takeaways for average investors.
First, Kodiak stock has done very well over the past year. During that time, shares have risen a staggering 564%. So, it’s no surprise that a biotech-focused firm like Boxer Capital has aggressively added to its position in the company. Kodiak now represents the firm’s third largest position by asset value, comprising approximately 7% of the firm’s total AUM.
While it may be tempting for retail investors to chase this spectacular rally, there are risks in doing so. First, the biotech sector is notorious for its volatility. This is due to the nature of the industry. Companies spend a lot to develop effective treatments, which often show promising early results. However, during clinical trials and the government approval process, a certain percentage of these treatments lose their luster. As a result, biotech stocks often rise in value, only to later collapse when bad news comes in the form of disappointing clinical trials or Food and Drug Administration (FDA) rejections.
As a result, many investors, especially risk-averse investors, would be wise to consider a biotech ETF, which helps reduce volatility by spreading risk among multiple stocks within the sector.
Before buying stock in Kodiak Sciences, consider the following:
I The Motley Fool Stock Advisor a team of analysts has just identified what they believe to be 10 best stocks for investors to buy now… and Kodiak Sciences was not one of them. The 10 stocks that made the cut could produce huge gains in the coming years.
Think about when Netflix made this list on December 17, 2004… if you invested $1,000 during our recommendation, you will have $534,008!* Whenever Nvidia made this list on April 15, 2005… if you invested $1,000 during our recommendation, you will have $1,090,073!*
Now, it’s worth noting Stock Advisor’s the average total return is 949% – outperformed the market by 190% for the S&P 500. Don’t miss the latest top 10 list, available via Stock Advisorand join an investment community built by individual investors for individual investors.
See 10 stocks »
*Stock Advisor returns from 9 March 2026.
Jake Lerch has no position in any of the stocks mentioned. The Motley Fool recommends Kymera Therapeutics. The Motley Fool has a policy of disclosure.
Investment Firm Doubles Down on Biotech Stock, Adds 386,000 Shares, According to Latest SEC Filing was first published by Motley Fool.
